GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2018
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
2 registry-linked trialsAbstract readPractice Guideline
In one paragraph
Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 577 papers, 12 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
577citing papers in PubMed, 12 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer
NCT04920708 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation
Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Who cites it
577 citing papers in PubMed, 12 syntheses or guidelines pooled it.
- SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Association of germlineFrontiers in pharmacology · 2026Pooled it
- Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis.Frontiers in oncology · 2026Pooled it
- Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis.Breast cancer research and treatment · 2025Pooled it
- Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in theFrontiers in pharmacology · 2025Pooled it
- Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Comparative efficacy and safety of eribulin versus paclitaxel in breast cancer: a systematic review and meta-analysis.Future oncology (London, England) · 2024Pooled it
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.BMC cancer · 2024Pooled it
- Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.ESMO open · 2023Pooled it
- Trial
- Trial
- Trial
- Overall Survival with Inavolisib inThe New England journal of medicine · 2025Trial
- Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial).Drug design, development and therapy · 2025Trial
- Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.Oncology research and treatment · 2025Trial
- Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.The New England journal of medicine · 2023Trial
517 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
F CardosoEuropean School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. Electronic address: fatimacardoso@fundacaochampalimaud.pt.
E SenkusEuropean Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
A CostaEuropean School of Oncology, Milan, Italy.
E PapadopoulosEuropa Donna Cyprus, Nicosia, Cyprus.
M AaproOncology Department, Clinique de Genolier, Genolier, Switzerland.
F AndréDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
N HarbeckBreast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany.
B Aguilar LopezDirection Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico.
C H BarriosDepartment of Oncology, PURCS School of Medicine, Porto Alegre, Brazil.
J BerghDepartment of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden.
L BiganzoliEuropean Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy.
C B Boers-DoetsCB Boers Organization, Wormer, The Netherlands.
M J CardosoBreast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal.
L A CareyDepartment of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
J CortésDepartment of Oncology, Vall d' Hebron University, Barcelona, Spain.
G CuriglianoDivision of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy.
V DiérasGynaecology and Breast Department, Centre Eugène Marquis, Rennes, France.
N S El SaghirBreast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon.
A EniuBreast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania.
L FallowfieldSHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK.
P A FrancisDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
K GelmonMedical Oncology Department, BC Cancer Agency, Vancouver, Canada.
S R D JohnstonDepartment of Medicine, The Royal Marsden, Sutton, UK.
B KaufmanDepartment of Oncology, Sheba Medical Center, Ramat Gan, Israel.
S KoppikarDepartment of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India.
I E KropBreast Oncology Center Dana-Farber Cancer Institute, Boston, USA.
M MayerAdvanced BC.org, New York, USA.
G NakiguddeAdvocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda.
B V OffersenEuropean Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
S OhnoCancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan.
O PaganiInstitute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland.
S Paluch-ShimonOncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel.
F Penault-LlorcaDepartment of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France.
A PratIDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain.
H S RugoBreast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.
G W SledgeOncology Division, Stanford University Medical Center, Stanford, USA.
D SpencePolicy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia.
C ThomssenDepartment of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany.
D A VorobiofOncology Department, Sandton Oncology Centre, Johannesburg, South Africa.
B XuDepartment of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
L NortonBreast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York.
E P WinerDana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA.
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MNCI NIH HHS P30 CA016086
Abstract
PubMed holds no abstract for this paper.
Indexed as
Consensus Statements as TopicBiomarkers, TumorBiopsy, Large-Core NeedleBreastBreast NeoplasmsChemoradiotherapy, AdjuvantClinical Trials as TopicEuropeEvidence-Based MedicineFemaleHumansIntegrative MedicineMastectomyMedical OncologyNeoadjuvant TherapyNeoplasm StagingBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04858997ClinicalTrials.gov
NCT04920708ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.